Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “KRAS G12D Mutations”

43 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 43 results

Testing effectiveness (Phase 2)WithdrawnNCT06690281
What this trial is testing

A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal Malignancies

Who this might be right for
Gastrointestinal CarcinomaPancreatic CancerHepatocellular Cancer+5 more
National Cancer Institute (NCI)
Early research (Phase 1)Looking for participantsNCT07094204
What this trial is testing

Find a Suitable Dose of ASP5834 in Adults With Solid Tumors

Who this might be right for
Solid TumorNon-Small-Cell Lung CancerPancreatic Ductal Adenocarcinoma+1 more
Astellas Pharma Inc 364
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06949761
What this trial is testing

A Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of QLC1101 in Combination With Other Therapies in the Treatment of Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation

Who this might be right for
Solid Tumor
Qilu Pharmaceutical Co., Ltd. 240
Testing effectiveness (Phase 2)Looking for participantsNCT07259590
What this trial is testing

GFH375 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors Harboring KRAS G12D Mutation

Who this might be right for
Advanced Solid Tumors CancerPDACCRC (Colorectal Cancer)
Genfleet Therapeutics (Shanghai) Inc. 126
Early research (Phase 1)Looking for participantsNCT06619587
What this trial is testing

Evaluate Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination in Patients With Advanced Solid Tumors

Who this might be right for
Solid Tumor
Genentech, Inc. 410
Testing effectiveness (Phase 2)Looking for participantsNCT07438106
What this trial is testing

A Phase II Study of HRS-4642 Combined With AG (Nab-paclitaxel and Gemcitabine) as Conversion Therapy for Locally Advanced Pancreatic Cancer

Who this might be right for
Locally Advanced Pancreatic Cancer With KRAS G12D Mutation
The First Affiliated Hospital with Nanjing Medical University 30
Early research (Phase 1)Active Not RecruitingNCT06818812
What this trial is testing

Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation

Who this might be right for
Solid Tumors
Incyte Corporation 30
Early research (Phase 1)Looking for participantsNCT06403735
What this trial is testing

A Phase I Clinical Study of QLC1101 in Patients With Advanced Solid Tumors

Who this might be right for
Non-small Cell Lung CancerColorectal CancerPancreatic Cancer+1 more
Qilu Pharmaceutical Co., Ltd. 250
Large-scale testing (Phase 3)Looking for participantsNCT07522073
What this trial is testing

Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma

Who this might be right for
Solid Tumors
Incyte Corporation 588
Testing effectiveness (Phase 2)Looking for participantsNCT07023731
What this trial is testing

Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation

Who this might be right for
KRAS G12D MutationAdvanced Solid Cancer
Arvinas Inc. 159
Early research (Phase 1)Looking for participantsNCT06218914
What this trial is testing

Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors

Who this might be right for
Non-small Cell Lung CancerColorectal CarcinomaPancreatic Ductal Adenocarcinoma+3 more
AstraZeneca 108
Early research (Phase 1)Looking for participantsNCT06962254
What this trial is testing

Imatinib and Trametinib for KRAS-mutated Solid Tumor

Who this might be right for
Solid Tumor Cancer
China Medical University Hospital 10
Early research (Phase 1)Looking for participantsNCT07207707
What this trial is testing

Investigate the Safety and Efficacy of KQB548 in Participants With Advanced Solid Malignancies

Who this might be right for
Solid Tumor Malignancies
Kumquat Biosciences Inc. 78
Testing effectiveness (Phase 2)Looking for participantsNCT06500676
What this trial is testing

GFH375 in Patients With Advanced Solid Tumors With KRAS G12D Mutations

Who this might be right for
KRAS G12D MutationsAdvanced Solid Tumors
Genfleet Therapeutics (Shanghai) Inc. 407
Testing effectiveness (Phase 2)Looking for participantsNCT07240766
What this trial is testing

HRS-4642 in Combination With Nimotuzumab and Chemotherapy for BRPC With KRAS G12D Mutation

Who this might be right for
Borderline Resectable Pancreatic Adenocarcinoma
Zhejiang University 40
Testing effectiveness (Phase 2)Study completedNCT06208124
What this trial is testing

IMM-6-415 in RAS/RAF Mutant Solid Tumors

Who this might be right for
Advanced Solid Tumor (Phase 1)Pancreas AdenocarcinomaNon-small Cell Lung Cancer+1 more
Immuneering Corporation 30
Testing effectiveness (Phase 2)Looking for participantsNCT06385925
What this trial is testing

TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation

Who this might be right for
Malignant Neoplasm
Tyligand Pharmaceuticals (Suzhou) Limited 440
Testing effectiveness (Phase 2)Looking for participantsNCT06667544
What this trial is testing

RNK08954 in Subjects With Advanced Solid Tumors With KRAS ((Kirsten Rat Sarcoma) G12D Mutation

Who this might be right for
KRAS G12D Mutation
Ranok Therapeutics (Hangzhou) Co., Ltd. 152
Testing effectiveness (Phase 2)Looking for participantsNCT07020221
What this trial is testing

VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

Who this might be right for
Pancreatic Ductal AdenocarcinomaNon Small Cell Lung CancerColorectal Cancer+2 more
Verastem, Inc. 295
Large-scale testing (Phase 3)Not Yet RecruitingNCT07232875
What this trial is testing

HRS 4642 Injection Combined With AG Versus Placebo Combined With AG Therapy in First-Line Advanced or Metastatic Pancreatic Cancer

Who this might be right for
KRAS G12D-Mutant Advanced or Metastatic Pancreatic Cancer in the First-line Setting
Jiangsu HengRui Medicine Co., Ltd. 588
Load More Results